Re-Treatment of Chronic Pulmonary Tuberculosis with Low and High Dosages Rifampicin Regimens in the Continuation Intermittent Phase (A controlled comparison study)

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The great value of rifampicin as a suitable anti-tuberculous agent for intermittent therapy has been confirmed in several experimental and clinical studies. Unfortunately our actual knowledge of which size of doses should be chosen for rifampicin in the intermittent therapy after a preceding daily phase is still insufficient.